An observational study in Acute Cholecystitis, sponsored by Instituto de Investigación Sanitaria y Biomédica de Alicante. Recruiting at 1 site in Spain. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2025-06-08.
Sponsored by Instituto de Investigación Sanitaria y Biomédica de Alicante · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Cholecystitis, Acute with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Cholecystitis, Acute · Spain.
Among the 13 studies in Cholecystitis, Acute with a site in Spain, this one is one of 2 that started in 2025, is one of 5 observational ones, and was the 11th registered.
140 studies on the registry are indexed under Cholecystitis, Acute; 30 are open to participants now.
Browse Cholecystitis, Acute studies →7 of the 13 studies in Cholecystitis, Acute with a site in Spain are open now. Recruiting first, the newest first:
Hospital General Universitario de Alicante · Sites in Spain
Ages 18+
Hospital Arnau de Vilanova · Sites in Spain
Ages 18+
Corporacion Parc Tauli · Sites in Spain
Ages 18–100
Fundacion Miguel Servet · Sites in Spain
Hospital del Mar · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 21 Cholecystitis, Acute studies recruiting now, 17 (81%) set no upper age limit and 2 (10%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 1 · Phase 4 1
First in 2013; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 376 is above the median of 216 across 52 observational studies indexed under Cholecystitis, Acute.
Median enrollment 146 across the 8 interventional studies, 600 across the 5 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 10 most frequent:
Instituto de Investigación Sanitaria y Biomédica de Alicante is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Instituto de Investigación Sanitaria y Biomédica de Alicante has 1 study filed under Cholecystitis, Acute — fewer than ten, so there is no comparison to draw.
2 of the studies in Cholecystitis, Acute with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07481760Hospital del MarAcute Cholecystitis Biliary Complications - ICG | 2027-01-01 |
| NCT07006298Instituto de Investigación Sanitaria y Biomédica de AlicanteOne-year Outcomes by Index Treatment in Elderly Patients With Acute Cholecystitis | 2027-05-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Cholecystitis, Acute with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background: The GOLDENEYE study is an international, multicenter, prospective observational investigation designed to compare the outcomes of various management strategies for acute cholecystitis in patients aged 70 years and older. This research is driven by the increasing prevalence of gallstones and biliary tract diseases in the elderly, alongside a recognition that the burden of comorbidity in this population may necessitate tailored treatment approaches to optimize outcomes.
Patients and Methods: The primary aims of the study are to evaluate the efficacy of different treatments -supportive care, percutaneous gallbladder drainage, early or delayed cholecystectomy, and EUS-guided gallbladder drainage- on patient-centric outcomes, including one-year additional treatment modalities, hospital readmissions, outpatient encounters, quality of life, and survival rates. The study adopts a robust design incorporating propensity score matching analysis to account for the non-randomized allocation of treatment modalities, thereby minimizing selection bias and enhancing the comparability of treatment groups. Inclusion criteria are centered on patients ≥70 years diagnosed with acute cholecystitis, as per the Tokyo guidelines, while key exclusion criteria include prior episodes of cholecystitis or pancreatitis, terminal illness, and concurrent diagnosis of acute pancreatitis, cholangitis, bile duct disease, or digestive malignancy. Data collection will leverage the REDCap platform for systematic and secure data management, facilitating real-time data entry and monitoring across participating centers.
Discussion: This comprehensive approach ensures the integrity and reliability of data collected on demographics, gender, clinical outcomes, and quality of life measures. Through its innovative design and methodology, the GOLDENEYE study aims to generate evidence-based insights that will significantly influence the management of acute cholecystitis in the elderly, ultimately improving patient outcomes and healthcare practices in this growing demographic population.
Patients ≥70 years diagnosed with acute cholecystitis, as per the Tokyo guidelines
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients that received antibiotics only
Patients that undergo early or delayed cholecystectomy
Patients that undergo percutaneous gallbladder drainage
Patients that undergo EUS-guided gallbladder drainage
1 year additional procedures, hospital readmissions or outpatient visits
Percentage of patients requiring any additional procedure, hospital readmission or outpatient visit during the first year.
Time frame: 1 year
1-year health-related quality of life
The EQ-5D-5L questionnaire is used to assess quality of life in elderly individuals. It encompasses five key dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is evaluated across five severity levels. Level 1 indicates that the patient has no problems. Level 5 indicates the worst condition. Additionally, the questionnaire has a scale. This scale is numbered from 0 to 100. A score of 100 indicates the best health possible. Zero means the worst health possible. Measurements will be obtained during the initial admission and at one, three, and twelve months.
Time frame: 1 year
1-year overall survival
Survival will be defined as the time elapsed between the date of index admission and the date of death or last follow-up. Survival curves will be constructed by the Kaplan-Meier method and compared using the log-rank test. A multivariable Cox proportional hazards regression model will be used to identify prognostic factors associated with survival. All variables that are significant at 0.10 in the univariable analysis will be entered into a multivariable model. P-values less than 0.05 will be considered statistically significant. All analyses will be performed with RStudio, version 1.2.5001 (Integrated Development for R. RStudio, Inc., Boston, MA, USA).
Time frame: 1 year
Plan to share: No — The Steering Committee and statistical advisors will have access to the final dataset. Members of the GOLDENEYE study that recruited patients may claim access to the final dataset to perform ancillary studies; the Steering Committee will study these proposals. Any data required to support the protocol can be supplied on request.
Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.
Of 22 observational studies under Cholecystitis, Acute, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's planned 24 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto de Investigación Sanitaria y Biomédica de Alicante